纳米白蛋白结合型紫杉醇的疗效似乎与转移性乳腺癌中的SPARC表达无关。

Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer.

作者信息

Schneeweiss Andreas, Seitz Julia, Smetanay Katharina, Schuetz Florian, Jaeger Dirk, Bachinger Andreas, Zorn Markus, Sinn Hans-Peter, Marmé Frederik

机构信息

National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany

National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany Department of Gynecology and Obstetrics, University Hospital Heidelberg, Heidelberg, Germany.

出版信息

Anticancer Res. 2014 Nov;34(11):6609-15.

DOI:

PMID:25368265

Abstract

AIM

To evaluate the predictive value of the expression of the secreted protein acidic and rich in cysteine (SPARC) for nab-paclitaxel in metastatic breast cancer (MBC).

PATIENTS AND METHODS

Forty-four patients with progressive MBC were prospectively treated with nab-paclitaxel. Expression of SPARC in tumor cells was assessed by an immunoreactive score, integrating staining intensity and percentage of positive tumor cells; expression in stroma based on staining intensity. SPARC serum levels were determined before 1st and 2nd cycle of nab-paclitaxel and at progression. By applying several cut-offs the association between SPARC expression or serum levels and clinical end-points was analyzed.

RESULTS

No clear association between expression of SPARC in primary or metastatic tumor tissue or in serum and any clinical end-point could be detected regardless of the various cut-offs applied.

CONCLUSION

Efficacy of nab-paclitaxel in MBC does not seem to be associated with expression of SPARC in tumor tissues or serum.

摘要

目的

评估富含半胱氨酸的酸性分泌蛋白（SPARC）的表达对转移性乳腺癌（MBC）中纳米白蛋白结合型紫杉醇疗效的预测价值。

患者与方法

44例进展期MBC患者接受纳米白蛋白结合型紫杉醇前瞻性治疗。通过免疫反应评分评估肿瘤细胞中SPARC的表达，该评分综合了染色强度和阳性肿瘤细胞百分比；基于染色强度评估基质中的表达。在纳米白蛋白结合型紫杉醇第1周期和第2周期之前以及疾病进展时测定SPARC血清水平。通过应用多个临界值，分析SPARC表达或血清水平与临床终点之间的关联。